I’m going to also go on a rant on #5
I treat a lot of skin. A LOT. Orthovoltage, electrons, VMAT, you name it. Converting some of my breast consult space for even more skin space between my RO skin partner and I.
The wild west is probably a good way of putting it. I spent a lot of my time early on in my (still junior) practice on reviewing strategies here. I could go on a rant here for about an hour on how no one can agree on how to treat this.
I‘ll attach a few dose and fractionations that come from different sources. Note whiel there are some commonalities, in other cases they are WILDLY different.
ASTRO guidelines:
View attachment 359637
NCCN:
View attachment 359638
Some US dermatology guidelines:
View attachment 359639
This one I think is hilarious because it references ‘Total Dose Fractions’ and puts the units in Gy instead of its proper/original nomenclature.
Taken from the old Orton and Ellis tables courtesy this book:
View attachment 359647
View attachment 359640
View attachment 359641
From a UK patterns of practice survey, McPartlin BJR 2014
View attachment 359642
View attachment 359643
One opinion paper post covid suggests rather hypofrac/descalation of treatment for a lot of these frail patients:
View attachment 359645
Let alone some of the more recent skin SBRT publications looking at dose escalated treatment for more bulky skin cancers.
Heck, someone I used to train with used what is usually published as a HDR brachy dose with good effect, also not in any of these above. ‘The secret sauce’
One thing I’ve tried to come to terms with is what is an effective tumorcidal dose? It’s nice to try and say to give a 85 yr old 30 fractions but it’s really not practical and there are other good hypofractionation options that may be more suitable.
Also what’s hard with this - a lot of these institutional outcomes don’t report technique well. Few places have access to superficial radiotherapy, electrons are a lot more common in places that have linacs. Are these corrected for RBE, do they even need to be corrected to RBE? Are they being prescribed to 90%, is this being prescribed to Dmax? A lot of these details are not reported, and I think it matters.
What I will say which (somewhat) perplexes me and have given some thought to, is a lot of these doses if you look at more of the moderate/extreme hypofraction (eg 5-10 fr), the linear quadratic model starts to break down for what is tumorcidal for non-bulky tumors, as compared to conventional 2Gy/fr. There does seem to be a time element that is not well captured there. There may be something to using the tdf tables, for which most/all of these doses do fall along in the ‘sweet spot’ for. Probably because they are derived from this, and not vice versa. Is there difference in LC between a tumorcidal 5 fr/7 fr/10fr/20 fr/30fr regimen? Maybe? We can’t well tease it out from our current data I think.
The Zaorsky meta-analysis is good, but without good randomized data, I don’t know if one can’t really say I think since treatments can differ in technique by quite a bit.
What to do for definitive melanoma? What is effective palliation for melanoma/SCC on IO - is daily treatment truly the best?
This stuff drives me nuts. I wish we had better trials and data past - “we did this and it worked”
Also - if anyone has thoughts on above, would LOVE their insight & experience. I’m all ears.